Literature DB >> 12935963

Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia.

Anna Falanga1, Frederick R Rickles.   

Abstract

Life-threatening bleeding, which remains a challenging complication of acute leukaemia, is particularly characteristic of the subtype, acute promyelocytic leukaemia (APL). The clinical picture and laboratory abnormalities are most compatible with the diagnosis of disseminated intravascular coagulation (DIC). Evidence for diffuse activation of the coagulation system, hyperfibrinolysis and systemic elaboration of non-specific protease activity can usually be demonstrated and occurs most commonly during induction chemotherapy. While both host- and tumour-associated mechanisms can be implicated in the pathogenesis of the coagulopathy, leukaemic cell properties appear to be the proximate cause of activation of the haemostatic mechanisms. In this chapter we summarize the current state of knowledge of the pathogenesis of the coagulopathy of APL and the therapeutic approaches that have proved most useful for the management of this complication. Special attention is devoted to the use of all-trans-retinoic acid (ATRA), which has revolutionized the treatment of APL and markedly ameliorated the APL-related coagulopathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12935963     DOI: 10.1016/s1521-6926(03)00059-8

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  16 in total

Review 1.  Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia.

Authors:  Arturo J Martí-Carvajal; Vidhu Anand; Ivan Solà
Journal:  Cochrane Database Syst Rev       Date:  2015-06-24

2.  Transient ischemic attack as an unusual initial manifestation of acute promyelocytic leukemia.

Authors:  Lifeng Liu; Xiaoling Yuan
Journal:  Int J Hematol       Date:  2016-03-16       Impact factor: 2.490

3.  The biological characteristics of adult CD34+ acute promyelocytic leukemia.

Authors:  Ebtesam Ibrahim Ahmad; Hosneia Kh Akl; Mona E Hashem; Tarek Ali M Elgohary
Journal:  Med Oncol       Date:  2011-03-12       Impact factor: 3.064

Review 4.  The immunomodulatory role of all-trans retinoic acid in tumor microenvironment.

Authors:  Guoshu Bi; Jiaqi Liang; Yunyi Bian; Guangyao Shan; Valeria Besskaya; Qun Wang; Cheng Zhan
Journal:  Clin Exp Med       Date:  2022-07-13       Impact factor: 5.057

5.  Tetra-arsenic tetra-sulfide (As4S 4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.

Authors:  Yanfeng Liu; Pengcheng He; Feng Liu; Naicen Zhou; Xiaoyan Cheng; Lili Shi; Huachao Zhu; Jing Zhao; Yuan Wang; Mei Zhang
Journal:  Tumour Biol       Date:  2014-01-16

6.  Do circulating tumor cells play a role in coagulation and thrombosis?

Authors:  Garth W Tormoen; Kristina M Haley; Ross L Levine; Owen J T McCarty
Journal:  Front Oncol       Date:  2012-09-10       Impact factor: 6.244

7.  Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.

Authors:  Anna Falanga; Laura Russo; Carmen J Tartari
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-21       Impact factor: 2.576

8.  The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature.

Authors:  Pau Montesinos; Miguel A Sanz
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-04       Impact factor: 2.576

9.  Arsenic trioxide downregulates cancer procoagulant activity in MCF-7 and WM-115 cell lines in vitro.

Authors:  Ewelina A Hoffman; Katarzyna Gizelska; Marek Mirowski; Wojciech Mielicki
Journal:  Contemp Oncol (Pozn)       Date:  2015-05-13

10.  Arsenic sulfide promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.

Authors:  Yuwang Tian; Yanfeng Liu; Pengcheng He; Feng Liu; Naicen Zhou; Xiaoyan Cheng; Lili Shi; Huachao Zhu; Jing Zhao; Yuan Wang; Mei Zhang
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.